Speed, flexibility and innovation: Rethinking the way the biopharma industry operates 29-Nov-2021 By Jane Byrne A new report reveals that “speed-to-market” has jumped up from a lower-ranking business driver before the pandemic to the top priority today for biopharma companies, overtaking cost-based considerations by a healthy margin.